Table III.

Bioequivalence Assessment between the Products Used in Study 1 (ACV-US versus ACV-UK) and in Study 2 (ACV-AT versus ACV-US). Values are Geometric mean Ratios (Lower - Upper 90% Confidence Interval) for n = 10 Subjects

Study 1	US-C+/US-Ref	UK-Test/US-Ref	UK-Test/US-C+	UK-Test/US-Ave a
Uptake	0.87 (0.75–1.01)	0.61 (0.51–0.72)	0.70 (0.58–0.84)	0.65 (0.55–0.77)
Clearance	0.94 (0.76–1.17)	0.58 (0.44–0.76)	0.61 (0.43–0.88)	0.59 (0.44–0.81)
Study 2	AT-C+/AT-Ref	AT-Ref/US-Test	AT-C+/US-Test	AT-Ave/US-Test a
Uptake	1.12 (0.90–1.40)	1.61 (1.22–2.11)	1.81 (1.32–2.48)	1.70 (1.30–2.24)
Clearance	0.86 (0.69–1.07)	1.99 (1.56–2.54)	1.71 (1.41–2.07)	1.84 (1.52–2.23)

^aRatios involving US-Ave and AT-Ave were calculated using the geometric mean of 4 replicates (from Ref and C+ combined) for Q_up and Q_Cl in each subject